MX2023002797A - Composiciones activadoras de sting polivalente y usos de las mismas. - Google Patents
Composiciones activadoras de sting polivalente y usos de las mismas.Info
- Publication number
- MX2023002797A MX2023002797A MX2023002797A MX2023002797A MX2023002797A MX 2023002797 A MX2023002797 A MX 2023002797A MX 2023002797 A MX2023002797 A MX 2023002797A MX 2023002797 A MX2023002797 A MX 2023002797A MX 2023002797 A MX2023002797 A MX 2023002797A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- treatment
- polyvalent
- sting
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 230000003213 activating effect Effects 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 229940044665 STING agonist Drugs 0.000 abstract 1
- RFCBNSCSPXMEBK-INFSMZHSSA-N c-GMP-AMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]3[C@@H](O)[C@H](N4C5=NC=NC(N)=C5N=C4)O[C@@H]3COP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 RFCBNSCSPXMEBK-INFSMZHSSA-N 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 230000002601 intratumoral effect Effects 0.000 abstract 1
- 239000000693 micelle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F293/00—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule
- C08F293/005—Macromolecular compounds obtained by polymerisation on to a macromolecule having groups capable of inducing the formation of new polymer chains bound exclusively at one or both ends of the starting macromolecule using free radical "living" or "controlled" polymerisation, e.g. using a complexing agent
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2438/00—Living radical polymerisation
- C08F2438/01—Atom Transfer Radical Polymerization [ATRP] or reverse ATRP
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063075560P | 2020-09-08 | 2020-09-08 | |
| PCT/US2021/049365 WO2022055929A1 (en) | 2020-09-08 | 2021-09-08 | Polyvalent sting activating compositions and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002797A true MX2023002797A (es) | 2023-05-04 |
Family
ID=80469374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002797A MX2023002797A (es) | 2020-09-08 | 2021-09-08 | Composiciones activadoras de sting polivalente y usos de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12036319B2 (https=) |
| EP (1) | EP4210707A4 (https=) |
| JP (1) | JP2023546316A (https=) |
| KR (1) | KR20230066019A (https=) |
| CN (1) | CN116490193A (https=) |
| AU (1) | AU2021340623A1 (https=) |
| BR (1) | BR112023004271A2 (https=) |
| CA (1) | CA3191593A1 (https=) |
| IL (1) | IL301190A (https=) |
| MX (1) | MX2023002797A (https=) |
| WO (1) | WO2022055929A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114805309A (zh) * | 2022-06-07 | 2022-07-29 | 中国药科大学 | 苯并杂环类化合物及其制备方法、药物组合物和应用 |
| CN117599199B (zh) * | 2023-11-20 | 2025-03-04 | 北京大学 | 用于靶蛋白水解的聚合物及其制备方法和用途 |
| CN120242033B (zh) * | 2025-06-03 | 2025-08-22 | 合肥市第一人民医院 | 一种纳米组装体及其制备方法和应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2934598B1 (en) | 2012-12-19 | 2018-04-18 | Board Of Regents, The University Of Texas System | Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway |
| US9840533B2 (en) | 2013-04-29 | 2017-12-12 | Memorial Sloan Kettering Cancer Center | Compositions and methods for altering second messenger signaling |
| WO2014179760A1 (en) | 2013-05-03 | 2014-11-06 | The Regents Of The University Of California | Cyclic di-nucleotide induction of type i interferon |
| PE20160080A1 (es) | 2013-05-18 | 2016-02-21 | Aduro Biotech Inc | Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon |
| JP2016538344A (ja) | 2013-11-19 | 2016-12-08 | ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ | 癌処置としてのｓｔｉｎｇアゴニストの使用 |
| US20180344758A1 (en) | 2014-12-17 | 2018-12-06 | Lipogen Llc | Method of Treating Cancer with cGAMP or cGAsMP |
| CA3016457A1 (en) * | 2016-03-02 | 2017-09-08 | The Board Of Regents Of The University Of Texas System | Sting activating nanovaccine for immunotherapy |
| PE20210255A1 (es) | 2016-12-01 | 2021-02-10 | Takeda Pharmaceuticals Co | Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon) |
| EP3691640A1 (en) * | 2017-10-05 | 2020-08-12 | GlaxoSmithKline Intellectual Property Development Limited | Methods for administering sting agonists |
| WO2019161171A1 (en) | 2018-02-16 | 2019-08-22 | Sperovie Biosciences, Inc. | Nanoparticle formulations of sting agonists |
| US11096899B2 (en) * | 2018-09-07 | 2021-08-24 | Wisconsin Alumni Research Foundation | Bacterial membrane nanoparticles as an immunotherapy system for cancer treatment |
| JP7676331B2 (ja) * | 2019-06-22 | 2025-05-14 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 生分解性超ｐＨ感受性ポリマー |
-
2021
- 2021-09-08 AU AU2021340623A patent/AU2021340623A1/en active Pending
- 2021-09-08 JP JP2023515254A patent/JP2023546316A/ja active Pending
- 2021-09-08 BR BR112023004271A patent/BR112023004271A2/pt unknown
- 2021-09-08 CN CN202180071894.1A patent/CN116490193A/zh active Pending
- 2021-09-08 EP EP21867478.6A patent/EP4210707A4/en active Pending
- 2021-09-08 MX MX2023002797A patent/MX2023002797A/es unknown
- 2021-09-08 US US17/469,111 patent/US12036319B2/en active Active
- 2021-09-08 IL IL301190A patent/IL301190A/en unknown
- 2021-09-08 WO PCT/US2021/049365 patent/WO2022055929A1/en not_active Ceased
- 2021-09-08 CA CA3191593A patent/CA3191593A1/en active Pending
- 2021-09-08 KR KR1020237010998A patent/KR20230066019A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3191593A1 (en) | 2022-03-17 |
| CN116490193A (zh) | 2023-07-25 |
| IL301190A (en) | 2023-05-01 |
| JP2023546316A (ja) | 2023-11-02 |
| BR112023004271A2 (pt) | 2023-04-04 |
| AU2021340623A1 (en) | 2023-04-13 |
| WO2022055929A1 (en) | 2022-03-17 |
| EP4210707A4 (en) | 2024-10-16 |
| US20220071903A1 (en) | 2022-03-10 |
| KR20230066019A (ko) | 2023-05-12 |
| EP4210707A1 (en) | 2023-07-19 |
| US12036319B2 (en) | 2024-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023002797A (es) | Composiciones activadoras de sting polivalente y usos de las mismas. | |
| WO2022261250A8 (en) | Therapeutics for the degradation of mutant braf | |
| JP5386359B2 (ja) | 少なくとも一種の抗新生物剤により誘発される痛みの治療における少なくとも一種のボツリヌス神経毒素の治療的利用 | |
| CY1119616T1 (el) | Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα | |
| MX2019000566A (es) | Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña. | |
| WO2015024667A8 (en) | Method for increasing expression of rna-encoded proteins | |
| CY1118373T1 (el) | Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| NZ701205A (en) | Optimised subcutaneous therapeutic agents | |
| JOP20200031A1 (ar) | طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة | |
| BR112018012641A2 (pt) | molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição. | |
| SA522432668B1 (ar) | طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين | |
| KR20180014042A (ko) | 약물을 전달하기 위한 가교된 히알루론산 및 이를 이용한 약학적 제제 | |
| Rosa et al. | Phα1β, a peptide from the venom of the spider Phoneutria nigriventer shows antinociceptive effects after continuous infusion in a neuropathic pain model in rats | |
| EP2422816A4 (en) | MEDICAMENTAL COMPOSITION FOR THE TREATMENT OF TUMORS WITH ANTINEOPLASTIC MICROSCOPEPROOF POLYMERES | |
| SA517390331B1 (ar) | تراكيب مصفوفة بوليمر موضعية تشتمل على تركيز عالي من هيالورونات الصوديوم المخمر حيوياً واستخداماتها | |
| SA522431748B1 (ar) | طرق لإنتاج أرجيناز 1 ناتج بمعاودة الارتباط الجيني بشري واستخداماته | |
| MX394918B (es) | Neurotoxinas botulinas para uso en terapia | |
| Emam et al. | Doxorubicin expands in vivo secretion of circulating exosome in mice | |
| BR112022009798A2 (pt) | Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer | |
| Rwandamuriye et al. | Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade | |
| MX2022007305A (es) | Mejoras en la administracion sin aguja. | |
| MX2022003051A (es) | Formulaciones para la administracion de farmacos. | |
| Lee et al. | Conformation-switchable helical polypeptide eliciting selective pro-apoptotic activity for cancer therapy | |
| ZA202302893B (en) | Agonists of stimulator of interferon genes sting |